ASH 2022 | Advances in immunotherapy for multiple myeloma and future outlooks
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses advances that have been made in immunotherapy for the treatment of multiple myeloma, including progress in bispecific antibodies, CAR-T cell therapy, and genetic screening of patients for precision medicine. Dr Cerchione also highlights advances that have been made in the relapsed/refractory (R/R) setting, and shares some insights into clinical trials in this space. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
